Inhibition and genetic ablation of the B7/CD28 T-cell costimulation axis prevents experimental hypertension. 2010

Antony Vinh, and Wei Chen, and Yelena Blinder, and Daiana Weiss, and W Robert Taylor, and Jörg J Goronzy, and Cornelia M Weyand, and David G Harrison, and Tomasz J Guzik
Cardiology Division, Emory University School of Medicine, 1639 Pierce Dr, Atlanta, GA 30322, USA.

BACKGROUND The pathogenesis of hypertension remains poorly understood, and treatment is often unsuccessful. Recent evidence suggests that the adaptive immune response plays an important role in this disease. Various hypertensive stimuli cause T-cell activation and infiltration into target organs such as the vessel and the kidney, which promotes vascular dysfunction and blood pressure elevation. Classically, T-cell activation requires T-cell receptor ligation and costimulation. The latter often involves interaction between B7 ligands (CD80 and CD86) on antigen-presenting cells with the T-cell coreceptor CD28. This study was therefore performed to examine the role of this pathway in hypertension. RESULTS Angiotensin II-induced hypertension increased the presence of activated (CD86(+)) dendritic cells in secondary lymphatic tissues. Blockade of B7-dependent costimulation with CTLA4-Ig reduced both angiotensin II- and deoxycorticosterone acetate (DOCA)-salt-induced hypertension. Activation of circulating T cells, T-cell cytokine production, and vascular T-cell accumulation caused by these hypertensive stimuli were abrogated by CTLA4-Ig. Furthermore, in mice lacking B7 ligands, angiotensin II caused minimal blood pressure elevation and vascular inflammation, and these effects were restored by transplantation with wild-type bone marrow. CONCLUSIONS T-cell costimulation via B7 ligands is essential for development of experimental hypertension, and inhibition of this process could have therapeutic benefit in the treatment of this disease.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008024 Ligands A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed) Ligand
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D000069594 Abatacept A fusion protein immunoconjugate of the extracellular domain of CTLA4 and the Fc domain of human IgG1. It functions as a T-cell co-stimulation blocker that inhibits TNF-ALPHA and prevents the activation of T-LYMPHOCYTES. It is used in the treatment of RHEUMATOID ARTHRITIS. BMS 188667,BMS-188667,BMS-224818,BMS224818,Belatacept,CTLA-4-Ig,CTLA4-Fc,CTLA4-Ig,CTLA4-Ig Immunoconjugate,Cytotoxic T Lymphocyte-Associated Antigen 4-Immunoglobulin,LEA29Y,Nulojix,Orencia,BMS 224818,BMS188667,CTLA4 Ig Immunoconjugate,Cytotoxic T Lymphocyte Associated Antigen 4 Immunoglobulin,Immunoconjugate, CTLA4-Ig
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Antony Vinh, and Wei Chen, and Yelena Blinder, and Daiana Weiss, and W Robert Taylor, and Jörg J Goronzy, and Cornelia M Weyand, and David G Harrison, and Tomasz J Guzik
January 1996, Annual review of immunology,
Antony Vinh, and Wei Chen, and Yelena Blinder, and Daiana Weiss, and W Robert Taylor, and Jörg J Goronzy, and Cornelia M Weyand, and David G Harrison, and Tomasz J Guzik
June 1995, Immunity,
Antony Vinh, and Wei Chen, and Yelena Blinder, and Daiana Weiss, and W Robert Taylor, and Jörg J Goronzy, and Cornelia M Weyand, and David G Harrison, and Tomasz J Guzik
April 2001, The Journal of clinical investigation,
Antony Vinh, and Wei Chen, and Yelena Blinder, and Daiana Weiss, and W Robert Taylor, and Jörg J Goronzy, and Cornelia M Weyand, and David G Harrison, and Tomasz J Guzik
January 2001, Transplantation proceedings,
Antony Vinh, and Wei Chen, and Yelena Blinder, and Daiana Weiss, and W Robert Taylor, and Jörg J Goronzy, and Cornelia M Weyand, and David G Harrison, and Tomasz J Guzik
December 1995, The Journal of experimental medicine,
Antony Vinh, and Wei Chen, and Yelena Blinder, and Daiana Weiss, and W Robert Taylor, and Jörg J Goronzy, and Cornelia M Weyand, and David G Harrison, and Tomasz J Guzik
May 2009, Cell,
Antony Vinh, and Wei Chen, and Yelena Blinder, and Daiana Weiss, and W Robert Taylor, and Jörg J Goronzy, and Cornelia M Weyand, and David G Harrison, and Tomasz J Guzik
July 1996, Journal of immunology (Baltimore, Md. : 1950),
Antony Vinh, and Wei Chen, and Yelena Blinder, and Daiana Weiss, and W Robert Taylor, and Jörg J Goronzy, and Cornelia M Weyand, and David G Harrison, and Tomasz J Guzik
March 2001, Blood,
Antony Vinh, and Wei Chen, and Yelena Blinder, and Daiana Weiss, and W Robert Taylor, and Jörg J Goronzy, and Cornelia M Weyand, and David G Harrison, and Tomasz J Guzik
January 2011, Frontiers in immunology,
Antony Vinh, and Wei Chen, and Yelena Blinder, and Daiana Weiss, and W Robert Taylor, and Jörg J Goronzy, and Cornelia M Weyand, and David G Harrison, and Tomasz J Guzik
January 1998, Critical reviews in immunology,
Copied contents to your clipboard!